Strategic Collaboration Overview
Tran‑Scell Biologics Private Limited, an India‑based biotechnology firm headquartered in Hyderabad, Telangana, and Space Cargo Unlimited, a Luxembourg‑based commercial space company based in Foetz, announced a strategic partnership to conduct pre‑clinical drug and vaccine testing in orbital microgravity. The collaboration combines Transcell’s validated human microphysiological systems (HMPS), AI/ML‑driven biology platforms, and proprietary biological foundation models with Space Cargo’s established mission architecture, regulatory pathways, and payload return capabilities.
Rationale and Expected Impact
Historically, only about one in ten drug candidates entering clinical development reaches regulatory approval, a shortfall often attributed to gaps between pre‑clinical models and human biology. By generating mechanistic evidence in microgravity—where cellular behaviour, tissue organisation, immune function and signalling differ markedly from Earth‑gravity conditions—the partners aim to produce more predictive, human‑relevant data. The intended outcomes are reduced late‑stage failures, accelerated discovery and development timelines, and support for the regulatory shift toward non‑animal New Approach Methodologies (NAMs).
Focus Areas
The initial research scope will target five therapeutic domains where prediction of human outcomes remains challenging: oncology, immunology, neurodegenerative diseases, metabolic disorders, and anti‑aging. The joint effort will offer pharmaceutical and biotechnology organisations space‑enabled NAMs to accelerate therapeutic and vaccine development.
Leadership Statements
Dr. Subhadra Dravida, Founder and Chief Executive Officer of Transcell Biologics, stated that microgravity broadens the observable spectrum of tissue architecture, cellular organisation and immune signalling, providing a distinctly human‑relevant evidence layer for pharmaceutical decision‑making. Nicolas Gaume, President of Space Cargo Unlimited, highlighted that the company’s BentoBox platform—a standardized, autonomous laboratory for in‑space experimentation—combined with end‑to‑end mission services, enables scalable and repeatable experiments, positioning microgravity as a new laboratory for therapeutic innovation.
About the Companies
Tran‑Scell Biologics Private Limited is an Indian biotechnology company that offers deployable, industrialised non‑animal NAMs to the global pharma industry. Its flagship offering, Digital Animal Replacement Technology (DART), leverages a portfolio of human microphysiological systems and AI/ML tools to transform drug and vaccine discovery and development workflows.
Space Cargo Unlimited is a Luxembourg‑based space enterprise focused on commercial in‑space manufacturing. Its BentoBox platform provides a standardized, autonomous laboratory for in‑space experiments and production, supported by comprehensive mission services from payload preparation through launch, in‑orbit operations, and payload return. By deploying this platform across multiple space vehicles, the company aims to create a scalable, fleet‑based model for the low‑Earth‑orbit economy.
Release Information
The press release was issued on Friday, 14 August 2026 at 11:08:13 IST, under an arrangement with Business Wire India. Contact details include Abhishek Akshantala (Tran‑Scell Biologics) and Francesca Byrne (AstroAgency).